C12N 2740/16311
Concerning hiv regulatory proteins
Official title: concerning HIV regulatory proteins
C12N2740/16311 (Concerning hiv regulatory proteins) appears on 613 US grants and 723 published applications in this corpus.
Search patents in C12N- Granted patents
- 613
- Published applications
- 723
- Assignees
- 399
- Inventors
- 1,261
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 2 | 0 |
| 1991 | 4 | 0 |
| 1992 | 2 | 0 |
| 1993 | 4 | 0 |
| 1994 | 6 | 0 |
| 1995 | 3 | 0 |
| 1996 | 8 | 0 |
| 1997 | 26 | 0 |
| 1998 | 22 | 0 |
| 1999 | 27 | 0 |
| 2000 | 26 | 0 |
| 2001 | 31 | 7 |
| 2002 | 30 | 29 |
| 2003 | 24 | 73 |
| 2004 | 17 | 41 |
| 2005 | 8 | 46 |
| 2006 | 23 | 47 |
| 2007 | 19 | 32 |
| 2008 | 22 | 51 |
| 2009 | 21 | 33 |
| 2010 | 21 | 52 |
| 2011 | 22 | 34 |
| 2012 | 35 | 31 |
| 2013 | 24 | 15 |
| 2014 | 26 | 23 |
| 2015 | 17 | 23 |
| 2016 | 15 | 19 |
| 2017 | 24 | 30 |
| 2018 | 18 | 21 |
| 2019 | 19 | 26 |
| 2020 | 16 | 18 |
| 2021 | 13 | 19 |
| 2022 | 12 | 21 |
| 2023 | 7 | 8 |
| 2024 | 12 | 10 |
| 2025 | 4 | 9 |
| 2026 | 2 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- HIV immunotherapy with no pre-immunization step18 Aug 2026US 12,709,753 B2American Gene Technologies International Inc.
- Infectious disease antigens and vaccines5 May 2026US 12,616,746 B2Seattle Project Corp.
- Modified HIV-1 proviral vectors with enhanced dendritic cell transduction efficiencies comprising the JRFL envelope23 Dec 2025US 12,503,499 B2University of Massachusetts
- Compositions and methods for studying the Tat gene12 Aug 2025US 12,385,069 B2Board of Regents of the Nevada System of Higher Education, on behalf of the University of Nevada
- Compositions and methods for treating T cell exhaustion29 Jul 2025US 12,370,217 B2HTYR Acquisition LLC
- Nanoparticle compositions and uses thereof for reactivation of latent hiv27 Aug 2026US 2026/0248880 A1The Trustees of the University of Pennsylvania
- Fusion protein for localized activation of t-cells20 Aug 2026US 2026/0242470 A1Medizinische Hochschule Hannover
- Use of modified hiv-1 for generating fully human antibodies2 Jul 2026US 2026/0184767 A1University of Massachusetts
- Anti-synucleinopathy peptide and methods to treat neurodegenerative diseases29 Jan 2026US 2026/0027179 A1The University of British Columbia
- Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody1 Jan 2026US 2026/0001939 A1Heidelberg ImmunoTherapeutics GmbH
Most cited
By later US patents
- Sugar modified oligonucleotides that detect and modulate gene expression641US 5,670,633 AIsis Pharmaceuticals, Inc. · 1997
- Substituted purines and oligonucleotide cross-linking603US 5,681,941 AIsis Pharmaceuticals, Inc. · 1997
- Genetic immunization277US 5,593,972 AThe Trustees of the University of Pennsylvania · 1997
- Expression and export technology of proteins as immunofusins276US 5,541,087 AFuji ImmunoPharmaceuticals Corporation · 1996
- Oligonucleotides having chiral phosphorus linkages234US 6,239,265 B1Isis Pharmaceuticals, Inc. · 2001